SHANDONG, China, July 27, 2020 (GLOBE NEWSWIRE) — After the COVID-19 outbreak, ECMO (Extracorporeal Membrane Oxygenation), has caught the eyes of the public. Regarded as the last resort to save severe COVID-19 patients, ECMO is used to sustain breathing for patients with severe cardio-pulmonary failure by providing continuous extracorporeal respiratory and circulatory assistance. As a top-level life-supporting equipment, ECMO is also known for its extremely high expense and scarcity worldwide.
Professor Liu Shuqin’s Team in Shandong University, China announced their recent achievements in developing a proto-type ECMO equipment. Professor Liu is Director of Maglev Engineering Research Center of the School of Electrical Engineering, Shandong University. Since 2008, the team has been studying the maglev artificial heart pump－the core component of ECMO. After more than ten years of conscientious research, the team has made breakthroughs in this field with technologies of independent intellectual property rights, and now are seeking cooperation to incubate the technology into real products. It is expected to save more lives of severe patients with the assistance of ECMO.
Also known as “mobile artificial heart-lung apparatus”, ECMO is a kind of Extracorporeal Membrane Oxygenation technology for sustaining lives of patients with acute or severe cardio-pulmonary failure. ECMO works mainly by pumping out the patient’s venous blood with a power pump (artificial heart), oxygenating the venous blood while discharging carbon dioxide through its membrane lung (artificial lung) and then again pumping the blood back into the patient’s body. Although ECMO has no curing effects on the infection caused by COVID-19, it provides effective gaseous exchange and functions as a substitute heart-and-lung system for critically ill patients by relieving their dyspnea－a sequela caused by the COVID-19’s attacking the lung of human beings. Thus ECMO is regarded as a “life-saving device” enabling medical staff to race against time in saving patients’ lives.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/afe16a5e-e81e-4948-b76b-b8ddc2697064
According to Professor Liu Shuqin, the Maglev Engineering Research Center of Shandong University is one of the earliest research institutes in China to conduct research on maglev technology. After more than ten years of strenuous efforts, the team of 16 members, with professional backgrounds covering electric engineering, computer technology, mechanics, fluid engineering, materials, chemistry, emergency medicine, cardiac surgery, intensive care medicine, etc., has independently developed an ECMO prototype. Adopting the maglev magnetic suspension technology, this equipment is characterized by low hemolysis, a sufficient pressure buffer, easy flow regulation, high safety reliability, small size, etc. The team has already carried out blood tests on animals. Parameters and indexes of the equipment have reached the world advanced level.
This equipment is expected to cut the prices of ECMO by one third. At present, each ECMO equipment costs over $200 thousand to $400 thousand, and operating consumables cost from $7 thousand to $11 thousand. According to Professor Liu Shuqin, if the ECMO equipment is produced on large scale, then the cost of each set of ECMO equipment and its consumables may drop to about $140 thousand and $4 thousand respectively. Cost reduction would promote wider availability of ECMO and benefits more patients.
In the reliability test, four centrifugal pumps of the ECMO prototype have been running smoothly for 15 consecutive days without failure. In the blood substitute (diluted glycerin) and blood tests, their performances have reached the international advanced level. Besides, the pump connector could be joined to imported equipment and even completely replace the imported ones given its excellent performance. At present, three patents for new inventions have been submitted for the maglev centrifugal pump, two of them have been authorized and one is going through material review.
“We hope that equipment manufacturing enterprises and medical institutions contact us as soon as possible so as to incubate our technology into products and make ECMO affordable to more patients in the near future,” Professor Liu said. After the ECMO prototype came out, many companies in Shenzhen, Shanghai, Beijing, Chengdu and other cities in China have already expressed their interests for cooperation.
According to Professor Liu, the current COVID-19 epidemic has become a severe challenge worldwide. The researchers hope the production of the ECMO equipment could provide help to people in urgent needs around the world.
Up to now, the team have obtained 9 invention patents and 3 utility model patents related to their artificial heart pump; and more than 100 papers have been published on this topic.